Skip to main content

Advertisement

SpringerLink
Log in

Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study seeks to evaluate the clinical characteristics of spondyloarthritis (SpA)-related uveitis in a cohort from South China and to assess the efficacy and safety of therapies based on TNF blockers. SpA patients with uveitis admitted to a south China hospital were enrolled. Demographic information, clinical characteristics, laboratory findings, intraocular inflammation, visual acuity, macular thickness, and treatments were documented. Of the 1,036 SpA patients reviewed, 182 had uveitis. Ankylosing spondylitis (AS) was the most common subtype. Unilateral uveitis was found in 51 cases (51/182, 28.0 %), and unilateral alternating uveitis was found in 75 cases (75/182, 41.2 %). Half of the cases were recurrent uveitis (52.2 %), and acute onset was common (76.4 %). The most serious complication was vision loss (0.5 %). No significant difference in disease activity was found between the SpA patients with or without uveitis. Predominant improvements were found in cases treated with all three anti-TNFs (infliximab, adalimumab, and etanercept) and anti-TNFs plus methotrexate (MTX). Monotherapy of methotrexate was not adequate for inducing remission. Monotherapy of etanercept was not as effective as adalimumab and infliximab, mainly in the prevention of recurrence. No significant difference in effectiveness was found among the three anti-TNFs if MTX was added. Etanercept plus MTX were well tolerated. Infliximab and adalimumab were associated with more tuberculosis and/or hepatitis flares. Uveitis is common in SpA patients. Severe complications may develop in prolonged and intractable cases. Treatments based on anti-TNFs had good clinical response, and better safety documentation were observed in etanercept plus MTX compared to the other two anti-TNF monoclonal antibodies plus MTX.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P et al (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88:1159–1162

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111:491–500

    Article  PubMed  Google Scholar 

  3. Liao S, Pan YF, Huang JL et al (2009) An epidemiological survey of low back pain and axial spondyloarthritis in a Chinese Han population. Scand J Rheumatol 38(6):455–459

    Article  CAS  PubMed  Google Scholar 

  4. Brophy S, Calin A (2001) Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 28:2283–2288

    CAS  PubMed  Google Scholar 

  5. Hajj-Ali RA, Lowder C, Mandell BF (2005) Uveitis in the internist’s office: are a patient’s eye symptoms serious? Cleve Clin J Med 72:329–339

    Article  PubMed  Google Scholar 

  6. Rosenbaum JT (1992) Acute anterior uveitis, and spondyloarthropathies. Rheum Dis Clin North Am 18:143–151

    CAS  PubMed  Google Scholar 

  7. Laval SH, Timms A, Edwards S, et al. (2001) Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 68(4):918–926

  8. Gran J, Skomsvoll J (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Rheumatology 15:766–771

    Article  Google Scholar 

  9. Chang JH, McCluskey PJ, Wakefield D (2005) Acute anterior uveitis and HLA-B27. Surv Ophthalmol 15:364–388

    Article  Google Scholar 

  10. Braun J, Baraliakos X, Listing J, Sieper J (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 15:2447–2451

    Article  Google Scholar 

  11. Pasadhika S, Rosenbaum JT (2014) Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 8:67–81

    PubMed Central  PubMed  Google Scholar 

  12. Santos Lacomba M, Marcos Martı´n C, Gallardo Galera JM et al (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251–255

    Article  CAS  PubMed  Google Scholar 

  13. De Smet MD (2006) RESCU participants. Infliximab for uveitis: forty six week efficacy and safety results from the Remicade European Study for Chronic Uveitis (RESCU). Inv Ophthalmol Vis 47: E-Abstract, 1525.

  14. Guignard S, Gossec L, Salliot C et al (2006) Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondyloarthropathy: a retrospective study. Ann Rheum Dis 65:1631–1634

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Sieper J, Rudwaleit M, Khan MA, Braun J (2006) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20:401–417

    Article  PubMed  Google Scholar 

  16. Rudwaleit M, van der Heijde D, Landewe R et al (2011) The Assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarrhtiritis in general. Ann Rheum Dis 70:25–31

    Article  CAS  PubMed  Google Scholar 

  17. Sieper J, Rudwaleit M, Baraliakos X, et al. (2009) The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68 Suppl 2

  18. Rothova A, van Veenedaal WG, Linssen A, Glasius E, Kijlstra A, de Jong PT (1987) Clinical features of acute anterior uveitis. Am J Ophthalmol 15:137–145

    Article  Google Scholar 

  19. Miettinen R, Saari M (1977) Clinical characteristics of familial acute anterior uveitis. Can J Ophthalmol 15:1–3

    Google Scholar 

  20. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondilytis Disease Activity Index. J Rheumatol 21:2286–2291

    CAS  PubMed  Google Scholar 

  21. Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285

    CAS  PubMed  Google Scholar 

  22. Jenkinson TR, Mallorie PA, Whitelock H, Kennedy LG, Garrett S, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 21:1694–1698

    CAS  PubMed  Google Scholar 

  23. van der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818

    Article  PubMed  Google Scholar 

  24. Jabs DA (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516

    Article  PubMed  Google Scholar 

  25. Age-Related Eye Disease Study Research Group (1999) The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no.1 Control. Control Clin Trials 20(6):573–600

    Article  Google Scholar 

  26. Nussenblatt RB, Peterson JS, Foster CS et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764–770

    Article  PubMed  Google Scholar 

  27. Sampaio-Barros PD, Pereira IA, Hernandez-Cuevas C et al (2013) An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. Clin Exp Rheumatol 31(4):484–489

    PubMed  Google Scholar 

  28. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG (1996) Causes of uveitis in the general practice of ophthalmology. Am J Ophthalmol 121(1):35–46

    Article  CAS  PubMed  Google Scholar 

  29. Zhang Z, Dai D, Yu K, Yuan F, Jin J, Ding L, Hao Y, Liang F, Liu N, Zhao X, Long J, Xi Y, Sun YY (2014) Association of HLA-B27 and ERAP1 with ankylosing spondylitis susceptibility in Beijing Han Chinese. Tissue Antigens 83(5):324–329

    Article  CAS  PubMed  Google Scholar 

  30. Qi J, Li Q, Lin Z, Liao Z, Wei Q, Cao S, Rong J, Hu Z, Yang M, Zhang Y, Lv Q, Huang J, Pan Y, Wu Y, Jin O, Li T, Gu J (2013) Higher risk of uveitis and dactylitis and older age of onset among ankylosing spondylitis patients with HLA-B*2705 than patients with HLA-B*2704 in the Chinese population. Tissue Antigens 82(6):380–386

    Article  CAS  PubMed  Google Scholar 

  31. Levy-Clarke G, Nussenblatt R (2006) Does anti-TNF therapy decrease the incidence of anterior uveitis in patients with ankylosing spondylitis? Nat Clin Pract Rheumatol 2(2):72–73

    Article  CAS  PubMed  Google Scholar 

  32. Greiner K, Murphy CC, Willermain F, Duncan L, Plskova J, Hale G et al (2004) Anti-TNF-alpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 45(1):170–176

    Article  PubMed  Google Scholar 

  33. Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A (2011) Adalimumab (HumiraTM): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol 31(2):165–173

    Article  PubMed  Google Scholar 

  34. Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113(12):2317–2323

    Article  PubMed  Google Scholar 

  35. Foster CS, Tufail F, Waheed NK et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121(4):437–440

    Article  CAS  PubMed  Google Scholar 

  36. Gangaputra S, Newcomb CW, Liesegang TL et al (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116(11):2188–2198

    Article  PubMed Central  PubMed  Google Scholar 

  37. Muñoz-Fernández S, García-Aparicio AM, Hidalgo MV et al (2009) Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye (Lond) 23(5):1130–1133

    Article  Google Scholar 

  38. Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, Bocchino ML, Sanduzzi A, Scarpa R (2014) The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 33(4):543–547

    Article  PubMed Central  PubMed  Google Scholar 

  39. Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884–1894

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Dixon WG, Hyrich KL, Watson KD et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522–528

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, Salemi S, D'Amelio R (2014) Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med 25(5):482–484

    Article  CAS  PubMed  Google Scholar 

  42. Carroll MB, Bond MI (2008) Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38:208–217

    Article  CAS  PubMed  Google Scholar 

  43. Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983–989

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21:1366–1371

    Article  CAS  PubMed  Google Scholar 

  45. Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, Su CA et al (1996) Prevalence of hepatitis B and C virus infections in the general Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun 5(1):62–73

    Article  Google Scholar 

  46. Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY et al (2011) A sero-epidemiological study on hepatitis C in China. Chin J Epidemiol 32(9):888–891

    Google Scholar 

  47. Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R (2014) Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33(2):273–276

    Article  PubMed  Google Scholar 

  48. Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, Lubrano E, Peluso R, Caso P, Galeazzi M, Punzi L, Scarpa R, Costa L (2015) Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther 15(5):641–650

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Project supported by National Natural Science Foundation of China (No. 81102270), Guangdong Natural Science Foundation (No. 2014A030313053, No.S2012010009075), and Fundamental Research Funds for the Central Universities of China (No. 11ykpy15).

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology & Clinical Immunology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080

    Fan Lian, Jun Zhou, Hanshi Xu, Liuqin Liang & Xiuyan Yang

  2. Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, China, 510080

    Cui Wei & Yu Wang

Authors
  1. Fan Lian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cui Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hanshi Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liuqin Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiuyan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lian, F., Zhou, J., Wei, C. et al. Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population. Clin Rheumatol 34, 1913–1920 (2015). https://doi.org/10.1007/s10067-015-2989-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2989-8

Keywords

Search

Navigation